Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:P52 vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newbury Pharmaceuticals AB Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Newbury Pharmaceuticals AB's Days Payable falls into.
Newbury Pharmaceuticals AB Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newbury Pharmaceuticals AB (FRA:P52) has a Days Payable of 0.00 as of Feb. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Newbury Pharmaceuticals AB and its competitors. Over the past decade, Newbury Pharmaceuticals AB's Days Payable has ranged from 54.57 to 289.66. According to the industry distribution chart, Newbury Pharmaceuticals AB ranks #348 out of 925 companies in the Drug Manufacturers industry, placing it in the top 37.6%.
Is Newbury Pharmaceuticals AB's Days Payable too high?
Newbury Pharmaceuticals AB's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 54.57 to a high of 289.66. Based on the distribution chart, Newbury Pharmaceuticals AB ranks #348 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Newbury Pharmaceuticals AB ranks #348 out of 925 companies for Days Payable. This puts Newbury Pharmaceuticals AB in the upper half of its industry. The industry median Days Payable is 88.85. Historically, Newbury Pharmaceuticals AB's own Days Payable has ranged from 54.57 to 289.66 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.85, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Newbury Pharmaceuticals AB and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newbury Pharmaceuticals AB's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Newbury Pharmaceuticals AB (FRA:P52) has a current Days Payable of 0.00. The stock's GF Value™ is €0.20, compared to a current price of €0.16 — trading 22.3% below its estimated fair value. The current Days Payable is 0.00. Newbury Pharmaceuticals AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (FRA:P52), the current Days Payable is 0.00 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newbury Pharmaceuticals AB (FRA:P52) Overvalued in 2026?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued.
The current stock price of €0.16 is trading 22.3% below its estimated GF Value™ of €0.20.
Key valuation signals for FRA:P52:
Days Payable: 0.00
GF Value™: €0.20 vs. price of €0.16 (22.3% below fair value)
No single metric tells the full story. See the FRA:P52 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score
Get the complete analysis for FRA:P52
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:P52 has been successfully added to your 
